Digital Health Leader Mark Hirschhorn Joins Hygieia Board as Company Ramps Up for Growth of Its Unique d-Nav® Insulin Management Technology

Demand grows for d-Nav, the first FDA-cleared technology to automatically adjust a medication dose

LIVONIA, Mich.–(BUSINESS WIRE)–Hygieia, a digital health company, is accelerating its operations as demand increases for d-Nav®, the only FDA-cleared technology that automates dose adjustments for patients who inject insulin. To help guide its aggressive growth initiatives, Hygieia has added Mark Hirschhorn, Talkspace president, COO and CFO, to its board of directors.

Hirschhorn will tap into his experience with telehealth giants Teladoc Health and Talkspace to advise Hygieia on its expansion strategy. At Teladoc, Hirschhorn was responsible for the company’s growth strategy, including the acquisition of BetterHelp, which he managed as the company grew into one of the largest online marketplaces for direct-to-consumer behavioral health. Under Hirschhorn’s leadership, Teladoc grew from $10M in revenue with 45 employees to $500M and 2,500 employees.

“Mark joins our board during a time of unprecedented company growth and in a market that is uniquely primed for innovation,” said Eran Bashan, Hygieia CEO and Co-Founder. “Mark has the perfect combination of expertise in the digital health industry and will help us navigate this transitional period.”

Hygieia is answering the increased demand for its unique d-Nav insulin management app. d-Nav uses AI-powered technology to automate an insulin dose adjustment. It is the first FDA-cleared technology to adjust a medication dose directly to the patient, acting as a surrogate for a physician giving users real-time recommendations.

The result is safe and effective insulin treatment that has nearly 90 percent of patients seeing improved A1c levels within 90 days.

“Today’s health care environment desperately needs medical technology solutions like d-Nav, which automate tasks and operate remotely,” says Hirschhorn. “I’m excited to join Hygieia’s board as the company begins to experience significant growth, and I’m looking forward to helping them drive better care for people with type 2 diabetes.”

“We believe the standard of insulin therapy needs to change so that every person injecting insulin gets frequent and regular titration. Only d-Nav can automate insulin dose adjustments at the user level. This is why we are readying for explosive growth,” said Bashan.

Also, Hygieia has augmented its advisory board with the addition of nationally recognized physician experts:

• Health insurance benefit design expert A. Mark Fendrick, M.D., is helping Hygieia shape its payment model to enable increased patient access to d-Nav.
• World-renowned endocrinologist George Grunberger, M.D., is advising Hygieia on physician and clinical outreach.

For more information on Hygieia and the d-Nav insulin management technology, visit hygieia.com or call 734-369-9980.

About Hygieia/ d-Nav Insulin Management Program

Hygieia is a specialty provider of insulin therapy and maker of the d-Nav® Insulin Management Program. The d-Nav program includes an AI-powered application that helps people with type 2 diabetes use insulin in a safe and effective way to control their blood sugar levels. Studies show that some 90 percent of people using d-Nav achieve lower A1C within three months. The d-Nav Insulin Management Program was developed by two University of Michigan researchers and has been peer-reviewed with studies published in leading medical journals. Hygieia is headquartered in Livonia, Michigan. Learn more at hygieia.com.

Contacts

Debbie Reinheimer, debbie@reinheimerpr.com, 248-227-3667